Amendments to the Specification

Replace the paragraph beginning on page 14, line 26 and ending on page 15, line16 with the following:

As can be seen in Table 2, all of the formulations contained HSPC, Chol, and DSPE, thus, they are referred to herein according to folic acid-PEG/mPEG content, as noted in the right-hand column of the table. Figs. 3A-3F schematically illustrate the liposomal formulations. Four folate-targeted liposome formulations were prepared (Figs. 3B, 3C, 3E, 3F); two formulations included a folic-acid-PEG conjugate prepared with PEG molecular weight of either 2000 Daltons (Fig. 3B; folic-acid-PEG_{2000})or ~~3500~~ 3350 Daltons (Fig. 3C; folic-acid-PEG_{3350}) and two formulations that included the folic-acid-PEG conjugate in addition to an mPEG-DSPE conjugate prepared with mPEG of molecular weight 2000 Daltons (Fig. 3E, folic acid-PEG_{2000}/mPEG and Fig. 3F, folic-acid-PEG_{3350}/mPEG). In all four formulations the folic acid-PEG- conjugate derived from PEG of molecular weight 2000 or 3350 Daltons was included at a molar fraction of 0.5% of total liposomal phospholipid. The two control formulations contained no folate (Figs. 3A and 3D) and differed in the mole fraction of $mPEG_{2000}$-DPSE included (0.5% and 7.5%, respectively).

Replace the paragraph on page 16, lines 11-18 with the following:

With continuing reference to Fig. 4A, addition of mPEG to the formulation or shortening of the PEG tether from 3350 to 2000 reduced the binding substantially. Binding was greater for M109**R**-HiFR cells than for M109**R**-LoFR cells for all of the liposome formulations. Interestingly, the highest affinity liposome formulation, *e.g.*, liposomes having the ~~folic acid-PEG_{3500}~~ folic acid-PEG_{3350}, showed the lowest relative increase of binding (~30%) when the LoFR and HiFR cells were compared.